Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) Q4 2018 Earnings Conference Call - Final Transcript
Mar 11, 2019 • 08:00 am ET
Good morning, ladies and gentlemen, and welcome to the Spring Bank March 11, 2019 Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions). As a reminder, this conference may be recorded.
I would like to now introduce the host -- your host for this conference call, John Freve, Chief Financial Officer of Spring Bank. Please go ahead, sir.
Good morning, everyone. Welcome to the Spring Bank Pharmaceuticals' fourth quarter and full year 2018 financial results and corporate update conference call. Joining me on this call from Spring Bank management team is Marty Driscoll, our President and Chief Executive Officer. The prepared remarks will be followed by a question-and-answer session.
Before I turn the call over to Marty, let me remind you that today's call will contain statements about the Company's future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. The words anticipate, could, plan, potential, expect, will, and other words denoting future events identify statements as forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those disclosed in our press release this morning as well as those disclosed and the Risk Factors section of our Form 10-K as filed today with the SEC, and other SEC reports. In addition, any forward-looking statements represent our views only as of today March 11, 2019, and should not be relied upon as representing our views as of any subsequent date.
And now, I would like to turn the call over to Marty Driscoll, the CEO of Spring Bank. Marty?
Thank you, John, and good morning, everybody, and thank you for joining us this morning. I believe many of you know that we had a very active and highly productive 2018, and we're looking forward to a similar milestone filled 2019. Our efforts in 2018 were highlighted by the continued advancement of our global inarigivir clinical development program for the treatment of chronic hepatitis B.
Data from our global Phase 2 ACHIEVE trial and other development efforts continued to demonstrate to us that inarigivir has the potential to be a simple, safe and selective oral treatment to elevate functional cure rates for patients with chronic HBV, as a backbone therapy in combination treatment strategies. We recently completed the final cohort of our ACHIEVE dose escalation trial, involving the 200 milligram dosing of inarigivir, and we are pleased to announce that a late-breaker abstract describing the top-line data from this cohort, and the entire study has been accepted for oral presentation at the general session at the year -- at the EASL International Liver Congress 2019, in Vienna that will take place in mid-April.
In anticipation of our combination therapy approach, a poster presentation involving inarigivir will also be presented at EASL, describing the impressive activity of inarigivir against capsid